DK3095793T3 - Reducering af udvaskning af protein A under en protein A-affinitetskromatografi - Google Patents

Reducering af udvaskning af protein A under en protein A-affinitetskromatografi Download PDF

Info

Publication number
DK3095793T3
DK3095793T3 DK16164203.8T DK16164203T DK3095793T3 DK 3095793 T3 DK3095793 T3 DK 3095793T3 DK 16164203 T DK16164203 T DK 16164203T DK 3095793 T3 DK3095793 T3 DK 3095793T3
Authority
DK
Denmark
Prior art keywords
protein
leaching
reduction
during
affinity chromatography
Prior art date
Application number
DK16164203.8T
Other languages
English (en)
Inventor
Robert L Fahrner
Amy Laverdiere
Paul J Mcdonald
Rhona M O'leary
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34193088&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3095793(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK3095793T3 publication Critical patent/DK3095793T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2845—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta2-subunit-containing molecules, e.g. CD11, CD18
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
DK16164203.8T 2003-07-28 2004-06-24 Reducering af udvaskning af protein A under en protein A-affinitetskromatografi DK3095793T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49050003P 2003-07-28 2003-07-28
EP04777121.7A EP1648940B1 (en) 2003-07-28 2004-06-24 Reducing protein a leaching during protein a affinity chromatography

Publications (1)

Publication Number Publication Date
DK3095793T3 true DK3095793T3 (da) 2020-05-25

Family

ID=34193088

Family Applications (2)

Application Number Title Priority Date Filing Date
DK16164203.8T DK3095793T3 (da) 2003-07-28 2004-06-24 Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
DK04777121.7T DK1648940T3 (da) 2003-07-28 2004-06-24 Reduktion af udvaskning af protein A under protein A-affinitetskromatografi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04777121.7T DK1648940T3 (da) 2003-07-28 2004-06-24 Reduktion af udvaskning af protein A under protein A-affinitetskromatografi

Country Status (14)

Country Link
US (2) US7485704B2 (da)
EP (3) EP3095793B1 (da)
JP (1) JP4599355B2 (da)
AU (1) AU2004265253B2 (da)
CA (1) CA2531595C (da)
DK (2) DK3095793T3 (da)
ES (1) ES2786568T3 (da)
HR (1) HRP20200589T1 (da)
HU (2) HUE050171T2 (da)
LT (1) LT3095793T (da)
PL (2) PL1648940T3 (da)
PT (1) PT3095793T (da)
SI (2) SI1648940T1 (da)
WO (1) WO2005016968A2 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
WO2005037869A2 (en) * 2003-10-15 2005-04-28 Applera Corporation Method of reducing leachate from protein a affinity media
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7483344B2 (en) 2005-02-14 2009-01-27 Quantum Corporation Compact picker systems and methods for automated storage libraries
EP2399605A1 (en) * 2005-02-23 2011-12-28 Genentech, Inc. Extending time to disease progression or survival in cancer patients
WO2006110292A2 (en) * 2005-03-25 2006-10-19 The Regents Of The University Of California Temperature-triggered immobilization and purification of antibodies
PE20070207A1 (es) * 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
EP1996716B1 (en) 2006-03-20 2011-05-11 The Regents of the University of California Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
SG174804A1 (da) 2006-09-13 2011-10-28 Abbott Lab
CA2673851C (en) * 2007-01-22 2016-05-03 Genentech, Inc. Polyelectrolyte precipitation and purification of proteins
JP2010520225A (ja) 2007-03-02 2010-06-10 ジェネンテック， インコーポレイテッド 低ｈｅｒ３発現に基づくｈｅｒ二量化インヒビターに対する応答を予測する方法
ES2751022T3 (es) 2007-07-09 2020-03-30 Genentech Inc Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos
US8940298B2 (en) * 2007-09-04 2015-01-27 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection
US20100291113A1 (en) * 2007-10-03 2010-11-18 Cornell University Treatment of Proliferative Disorders Using Antibodies to PSMA
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20110014607A (ko) * 2008-04-29 2011-02-11 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP2281000A2 (en) * 2008-05-15 2011-02-09 Novo Nordisk A/S Antibody purification process
TW201008580A (en) * 2008-06-03 2010-03-01 Abbott Lab Dual variable domain immunoglobulin and uses thereof
BRPI0913366A8 (pt) * 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US8822645B2 (en) * 2008-07-08 2014-09-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
EP2321338A1 (en) * 2008-08-14 2011-05-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
JP5155453B2 (ja) * 2008-09-15 2013-03-06 イー・エム・デイー・ミリポア・コーポレイシヨン タンパク質をベースとするアフィニティークロマトグラフィー樹脂からのタンパク質漏出を定量するための方法
US9109010B2 (en) 2008-10-20 2015-08-18 Abbvie Inc. Viral inactivation during purification of antibodies cross reference to related applications
CN102257006A (zh) * 2008-10-20 2011-11-23 雅培制药有限公司 使用a蛋白亲和层析分离和纯化抗体
SG162687A1 (en) † 2008-12-24 2010-07-29 Millipore Corp Caustic stable chromatography ligands
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
CA2751000A1 (en) 2009-03-11 2010-12-23 Wyeth Llc Methods of purifying small modular immunopharmaceutical proteins
JP5785941B2 (ja) * 2009-06-17 2015-09-30 アッヴィ・バイオセラピューティクス・インコーポレイテッド 抗ｖｅｇｆ抗体とその使用
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
WO2011015920A2 (en) * 2009-08-03 2011-02-10 Avesthagen Limited A highly efficient process of purification and production of recombinant trastuzumab
WO2011028811A2 (en) * 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
CN102666875A (zh) * 2009-10-15 2012-09-12 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
CN102753194B (zh) 2009-12-02 2015-07-08 伊麦吉纳博公司 靶向人前列腺特异性膜抗原的j591微抗体和双抗体
US20130178608A1 (en) * 2009-12-29 2013-07-11 Samir Kulkarni Protein purification by ion exchange
EP2519537A4 (en) * 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
WO2011153243A2 (en) * 2010-06-02 2011-12-08 Genentech, Inc. Anti-angiogenesis therapy for treating gastric cancer
CN103298834A (zh) 2010-08-03 2013-09-11 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US9046513B2 (en) 2010-08-26 2015-06-02 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
US9051375B2 (en) 2010-12-21 2015-06-09 The University Of Western Ontario Alkali-resistant variants of protein A and their use in affinity chromatography
JP5298242B2 (ja) 2010-12-21 2013-09-25 Ｊｓｒ株式会社 アフィニティークロマトグラフィー用担体およびイムノグロブリンを単離する方法
PL2766040T3 (pl) 2011-10-14 2019-11-29 Hoffmann La Roche Pertuzumab, trastuzumab, docetaksel i karboplatyna w leczeniu wczesnego stadium raka piersi
EP3608340A1 (en) 2011-11-23 2020-02-12 Medlmmune, LLC Binding molecules specific for her3 and uses thereof
JP2015508994A (ja) 2011-12-30 2015-03-26 アッヴィ・インコーポレイテッド Ｉｌ−１３および／またはｉｌ−１７に対する二重可変ドメイン免疫グロブリン
WO2014034644A1 (ja) 2012-08-27 2014-03-06 旭化成メディカル株式会社 温度応答性クロマトグラフィーによる抗体の精製方法
RU2636043C2 (ru) 2012-11-01 2017-11-17 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
MY173295A (en) 2013-04-16 2020-01-14 Genentech Inc Pertuzumab variants and evaluation thereof
WO2014186350A1 (en) * 2013-05-15 2014-11-20 Medimmune Limited Purification of recombinantly produced polypeptides
CA2918221A1 (en) 2013-07-15 2015-01-22 North Carolina State University Protease-resistant peptide ligands
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
JP6306189B2 (ja) * 2013-09-04 2018-04-04 イー・エム・デイー・ミリポア・コーポレイシヨン プロテインａ系親和性クロマトグラフィーカラムを洗浄する方法
EP3041593A4 (en) * 2013-09-05 2017-08-30 F. Hoffmann-La Roche AG Method for chromatography reuse
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
PT3116891T (pt) 2014-03-10 2020-05-18 Richter Gedeon Nyrt Purificação de imunoglobulina utilizando passos de pré-limpeza
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
EP3302551A2 (en) 2015-05-30 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP6851109B2 (ja) * 2016-06-16 2021-03-31 Jsr株式会社 抗体を精製する方法及び担体を洗浄する方法
TW201818940A (zh) 2016-11-04 2018-06-01 美商建南德克公司 Her2陽性乳癌之治療
MX2019007801A (es) 2016-12-28 2019-10-30 Genentech Inc Tratamiento de cáncer avanzado con expresión de her2.
EP3570884B1 (en) 2017-01-17 2020-09-30 Genentech, Inc. Subcutaneous her2 antibody formulations
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN117180422A (zh) 2017-03-02 2023-12-08 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
SG11202110947RA (en) 2019-04-02 2021-10-28 Bondwell Tech Inc Functionalized ubx protein materials for enhanced purification of antibodies
KR20220066161A (ko) * 2019-10-01 2022-05-23 리플리겐 코포레이션 유체의 단백질 농도 측정
US11224858B1 (en) 2020-10-01 2022-01-18 Immunicom, Inc. Reduced leaching of a ligand
JP2023544347A (ja) 2020-10-01 2023-10-23 イミューニコム， インコーポレイテッド リガンドの浸出の低減

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US4983722A (en) 1988-06-08 1991-01-08 Miles Inc. Removal of protein A from antibody preparations
JP2749167B2 (ja) 1988-06-21 1998-05-13 ジェネンテク，インコーポレイテッド 心筋梗塞の処置のための方法および治療用組成物
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
LU91067I2 (fr) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
ATE233813T1 (de) 1991-08-14 2003-03-15 Genentech Inc Veränderte immunglobuline für spezifische fc- epsilon rezeptoren
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69405251T2 (de) 1993-12-10 1998-02-05 Genentech Inc Methoden zur diagnose von allergie und prüfung anti-allergischer therapeutika
AP660A (en) 1994-01-18 1998-08-18 Genentech Inc A method of treatment of parasitic infection using IgE antagonists.
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5707622A (en) 1994-03-03 1998-01-13 Genentech, Inc. Methods for treating ulcerative colitis
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
DK0776396T3 (da) 1994-07-13 1999-07-26 Sca Hygiene Prod Ab Fremgangsmåde til fremstilling af et ikke-vævet materiale
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
IL125255A (en) 1996-01-23 2002-02-10 Genentech Inc Anti-cd18 antibodies for treating stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
NO304183B1 (no) * 1996-11-22 1998-11-09 Nyfotek As FremgangsmÕte for fremstilling av heksagonal faujasitt med lavt forbruk av organisk tilsetningsstoff, samt anvendelse av denne som katalysator ved alkylering
ATE267257T1 (de) 1996-11-27 2004-06-15 Genentech Inc Humanisierte anti-koerper gegen cd11a
PT1897890E (pt) 1996-11-27 2010-02-23 Genentech Inc Purificação por afinidade de um polipéptido numa matriz de proteína a
CA2286330C (en) 1997-04-07 2008-06-10 Genentech, Inc. Anti-vegf antibodies
JP2001511653A (ja) 1997-05-15 2001-08-14 ジェネンテク，インコーポレイテッド Ａｐｏ−２レセプター
US6281336B1 (en) 1998-06-09 2001-08-28 Statens Serum Institut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
KR100797308B1 (ko) 1999-06-25 2008-01-23 제넨테크, 인크. 인간화 항-ＥｒｂＢ2 항체 및 항-ＥｒｂＢ2 항체를 사용한치료 방법
DE60039448D1 (de) 1999-10-29 2008-08-21 Genentech Inc Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
DE10155984A1 (de) 2001-11-15 2003-05-28 Boehringer Ingelheim Pharma Verfahren zur Reduktion des Liganden-leakage von Affinitätschromatographie-Matrices
ES2319636T3 (es) * 2002-02-05 2009-05-11 Genentech, Inc. Purificacion de proteinas.
AU2004215653B2 (en) * 2003-02-28 2011-03-17 Lonza Biologics Plc. Antibody purification by protein A and ion exchange chromatography
PT3095793T (pt) 2003-07-28 2020-05-04 Genentech Inc Redução da lixiviação de proteína a durante a cromatografia por afinidade com proteína a
JP5731726B1 (ja) 2014-06-26 2015-06-10 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Also Published As

Publication number Publication date
AU2004265253B2 (en) 2011-09-01
US7485704B2 (en) 2009-02-03
EP3095793A1 (en) 2016-11-23
HUE050171T2 (hu) 2020-11-30
CA2531595C (en) 2015-12-08
DK1648940T3 (da) 2016-08-15
PT3095793T (pt) 2020-05-04
AU2004265253A1 (en) 2005-02-24
EP3095793B1 (en) 2020-03-25
JP2007526897A (ja) 2007-09-20
EP1648940B1 (en) 2016-04-27
PL1648940T3 (pl) 2016-12-30
SI1648940T1 (sl) 2016-08-31
WO2005016968A3 (en) 2005-04-21
JP4599355B2 (ja) 2010-12-15
HRP20200589T1 (hr) 2020-07-10
SI3095793T1 (sl) 2020-07-31
LT3095793T (lt) 2020-07-10
CA2531595A1 (en) 2005-02-24
US20050038231A1 (en) 2005-02-17
US20090099344A1 (en) 2009-04-16
PL3095793T3 (pl) 2020-09-07
EP1648940A2 (en) 2006-04-26
US7807799B2 (en) 2010-10-05
HUE029951T2 (en) 2017-04-28
EP3722309A1 (en) 2020-10-14
ES2786568T3 (es) 2020-10-13
WO2005016968A2 (en) 2005-02-24

Similar Documents

Publication Publication Date Title
DK3095793T3 (da) Reducering af udvaskning af protein A under en protein A-affinitetskromatografi
LTC1641823I2 (lt) GLP-1 analogo sulieti baltymai
DK1406656T3 (da) Fremgangsmåder til administrering af anti-TNF-alfa-antistoffer
EP1653801A4 (en) MODIFIED ANTIBODIES HAVING IMPROVED ANTIGEN BINDING AFFINITY
ATE484524T1 (de) Neue gegen den gewebefaktor gerichtete thrombomodulin-fusionsproteine als antikoagulantien
DK1737971T3 (da) Blandinger af bindingsproteiner
DK1752470T3 (da) GAG-bindende proteiner
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DK1350765T3 (da) Fremgangsmåde til fremstilling af jernoxider
NO20034452L (no) Sykdoms-assosiert protein
MX294935B (es) Regeneracion de fases estacionarias cromatograficas.
DE112004000857D2 (de) Eisen-Chrom-Aluminium-Legierung
DK1527690T3 (da) Fremgangsmåde til dearomatisering af valleprotein
DE10196287T1 (de) Bearbeitungsprogramm-Vorbereitungsvorrichtung
FI20031433A (fi) Menetelmä valikkojen muodostamiseksi
ATA14732002A (de) Spannvorrichtung
DE602004013668D1 (de) MPTP Affinitätsmarker
DE50309081D1 (de) Neue diketopyrrolopyrrolpigmente
DE602004007732D1 (de) Flüssigchromatographievorrichtung
ITMI20042063A1 (it) Giunto
DK1531920T3 (da) Chromatografisk fremgangsmåde
DE1309854T1 (de) Prozess-flash-chromatographie-säule
DE50208514D1 (de) Spannvorrichtung
NO20054532D0 (no) Fremgangsmater for a forhindre glukonoylering av proteiner
NO20053512D0 (no) IL-8-liknende proteiner